Neurocrine Biosciences Inc. has described new muscarinic M4 receptor antagonists reported to be useful for the treatment of tremor, dystonia and parkinsonism.
Researchers from Cerevel Therapeutics LLC presented data from a study that aimed to evaluate preclinical antipsychotic properties of M4 agonism while minimizing off-target side effects using novel muscarinic acetylcholine M4 receptor full and partial agonists, CV-0000042 (CVL-042) and CV-0000071, respectively.
